About HengRui USA

HengRui USA is a wholly owned subsidiary of our parent company Jiangsu Hengrui Medicine. The foundation of HengRui USA is rooted in our parent company Jiangsu Hengrui Medicine’s rich heritage of over 200 pipelines and products across therapeutic areas such as oncology, metabolics, autoimmune, pain management, etc.

Our work here at HengRui USA focuses on the multiple stages of the drug development process, from a clinical, regulatory, and pre-commercialization perspective. HengRui USA operates as the U.S. hub for our parent company from our home office location in Princeton, NJ. Strategic capabilities are being built to transition from a clinical-stage to commercial-stage biotechnology company.               ​

​About Jiangsu HengRui Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals is a global pharmaceutical company engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, surgical drugs, contrast agents and antibiotics. The company was established in 1970 and is headquartered in Lianyungang, Jiangsu. It was listed on the Shanghai Stock Exchange in 2000. It is also the largest listed pharmaceutical company in China. As of the end of 2019, it has more than 24,400 employees worldwide.

Jiangsu Hengrui Medicine Co., Ltd. established in 1970, is

• ​The largest manufacturer of antineoplastics in China
• Largest pharmaceutical company by market value in China
• No.1 in R&D spending among China pharmaceutical companies
• Ranked 47th among the TOP 50 list of global pharmaceutical companies   

Visit our Jiangsu Hengrui Pharmaceuticals website at www.hrs.com.cn